In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery

被引:106
作者
Cu, Yen
Booth, Carmen J. [2 ]
Saltzman, W. Mark [1 ]
机构
[1] Yale Univ, Dept Biomed Engn, MEC 414, New Haven, CT 06511 USA
[2] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06511 USA
关键词
Nanoparticle; Mucosal; Intravaginal delivery; Fluorescence; Surface modification; BIODEGRADABLE NANOPARTICLES; MUCOSAL VACCINATION; DRUG-DELIVERY; MOUSE VAGINA; HUMAN MUCUS; TRANSPORT; RATS; MICROSPHERES; IMMUNIZATION; DERIVATIVES;
D O I
10.1016/j.jconrel.2011.06.036
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Intravaginal (ivag) delivery, which is a proven way to confer local protection against STDs contracted via the reproductive tract, is complicated by the mucus gel barrier, the hormone cycle, and the harsh mucosal environment that leads to low residence-time for administered agents. Polymer delivery vehicles may be useful in overcoming these barriers. In this study, we explored the fate of nanoparticles (NP) made from poly (lactide-co-glycolide) (PLGA) in the mouse reproductive tract after ivag delivery. The nanoparticles were modified to display avidin (Avid-NP) or 2 kDa PEG (PEG-NP) on their surface. Vaginal retention fractions for bothmuco-adhesive Avid-NP and stealthy PEG-NP were 5x higher than unmodified PLGA particles (NP). The amount of particles associated with mucus differed across formulations (Avid-NP>NP>PEG-NP). PEG-NP was found at higher concentration in the tissue than Avid-NP and NP up to 6 h after delivery, and particles were found within epithelial cells, the underlying submucosal stromal and fibroblast cells of the vaginal tissue. Our results demonstrate that surface properties of nanoparticles can impact their fates following ivag delivery. Moreover, we show that the muco-evasive PEG-modified nanoparticles are the most effective among the delivery vehicles tested for this application. (C) 2011 Elsevier B. V. All rights reserved.
引用
收藏
页码:258 / 264
页数:7
相关论文
共 33 条
[1]   Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: The effect of mucus on particle adsorption and transport [J].
Behrens, I ;
Pena, AIV ;
Alonso, MJ ;
Kissel, T .
PHARMACEUTICAL RESEARCH, 2002, 19 (08) :1185-1193
[2]   Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres [J].
Brandhonneur, N. ;
Loizel, C. ;
Chevanne, F. ;
Wakeley, P. ;
Jestin, A. ;
Le Potier, M. F. ;
Le Corre, P. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 373 (1-2) :16-23
[3]   Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms [J].
Chatterton, BE ;
Penglis, S ;
Kovacs, JC ;
Presnell, B ;
Hunt, B .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 271 (1-2) :137-143
[4]   Barrier properties of mucus [J].
Cone, Richard A. .
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (02) :75-85
[5]   Controlled Surface Modification with Poly(ethylene)glycol Enhances Diffusion of PLGA Nanoparticles in Human Cervical Mucus [J].
Cu, Yen ;
Saltzman, W. Mark .
MOLECULAR PHARMACEUTICS, 2009, 6 (01) :173-181
[6]   Mucoadhesive microspheres for gastroretentive delivery of acyclovir:: In vitro and in vivo evaluation [J].
Dhaliwal, Sumeet ;
Jain, Subheet ;
Singh, Hardevinder P. ;
Tiwary, A. K. .
AAPS JOURNAL, 2008, 10 (02) :322-330
[7]   Synthesis of novel iodinated derivatives of nonoxynol-9 and their bioavailability in rats [J].
Fowler, PT ;
Matsumoto, K ;
Page, RC ;
Digenis, GA .
NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (07) :771-775
[8]   The vagina as a route for systemic drug delivery [J].
Hussain, A ;
Ahsan, F .
JOURNAL OF CONTROLLED RELEASE, 2005, 103 (02) :301-313
[9]   Mucosal dendritic cells [J].
Iwasaki, Akiko .
ANNUAL REVIEW OF IMMUNOLOGY, 2007, 25 :381-418
[10]   Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine [J].
Kanazawa, T. ;
Takashima, Y. ;
Hirayama, S. ;
Okada, H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 360 (1-2) :164-170